ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements
Mankind Pharma Limited has been assigned credit ratings by CARE Ratings Limited for ₹1,000 Crore in bank facilities. The long-term and short-term facilities received 'CARE AA+; Stable' and 'CARE A1+' ratings respectively. This assignment reflects the company's creditworthiness and stable financial outlook.
Mankind Pharma Ltd has completed the redemption of NCDs (INE634S07017) and paid total interest of ₹198.95 Crore across three NCD series on April 16, 2026. The total outflow for redemption and interest payments amounted to ₹1,448.95 Crore. This fulfills the company's scheduled debt obligations and reduces outstanding non-convertible debenture liabilities.
Mankind Pharma Limited's Board has approved the winding-up of its Sri Lankan wholly owned subsidiary, Mankind Pharma Lanka (Private) Limited. The entity had no active operations and became unviable due to regulatory changes. This closure is not expected to materially impact the company's consolidated financials.
Mankind Pharma Limited submitted a half-yearly statement for its listed privately placed debt securities ending March 31, 2026. The disclosure tracks three NCD series totalling ₹5,000 Crore in outstanding principal, with coupon rates between 7.97% and 7.99%.
Mankind Pharma Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar, KFin Technologies, confirmed that no requests for dematerialisation or rematerialisation of shares were received during the quarter.